| Full text | |
| Author(s): |
Rando, Daniela Goncales Galasse
;
Costa, Helena Gabrielle de Oliveira
;
Heitor, Thais Fernanda
;
de Moraes, Josue
;
Pavani, Thais Fernanda Amorim
Total Authors: 5
|
| Document type: | Journal article |
| Source: | CURRENT TOPICS IN MEDICINAL CHEMISTRY; v. 23, n. 9, p. 17-pg., 2023-01-01. |
| Abstract | |
Nitroaromatic compounds have been used for treating parasitic diseases since the 1960s. Pharmacological alternatives to treat them are under observation. However, for the most neglected diseases, such as those caused by worms and less known protozoans, nitro compounds are still among the drugs of choice, despite their well-known collateral effects. In this review, we describe the chemistry and the uses of the still most employed nitroaromatic compounds for treating parasitosis caused by worms or lesser-known protozoans. We also describe their application as veterinary drugs. The most accepted mechanism of action seems to be the same, leading to collateral effects. For this reason, a special session was dedicated to discussing toxicity, carcinogenicity, and mutagenesis, as well as the most acceptable aspects of the known structure-activity/toxicity relationships involving nitroaromatic compounds. It employed the SciFinder(n) search tool from the American Chemical Society in the search for the most relevant bibliography within the field, exploring keyword expressions such as "NITRO COMPOUNDS" and "BIOLOGICAL ACTIVITY" (within Abstracts or Keywords) and concepts related to parasites, pharmacology and toxicology. The results were classified according to the chemical classes of nitro compounds, being the most relevant studies regarding journal impact and interest of the described results chosen to be discussed. From the found literature, it is easy to notice that nitro compounds, especially the nitroaromatic ones, are still widely used in antiparasitic therapy, despite their toxicity. They also are the best starting point in the search for new active compounds. (AU) | |
| FAPESP's process: | 19/26686-2 - Schistosoma mansoni Cathepsin B1: design and rational synthesis of new potential inhibitors |
| Grantee: | Daniela Goncales Galasse Rando |
| Support Opportunities: | Regular Research Grants |
| FAPESP's process: | 20/01441-4 - Drug selection with anthelmintic properties, nanoencapsulation and preclinical evaluation in experimental model of schistosomiasis |
| Grantee: | Josué de Moraes |
| Support Opportunities: | Regular Research Grants |